PMID: 8448749Mar 1, 1993Paper

Etoposide in combination as first-line chemotherapy for advanced Hodgkin disease. A Cancer and Leukemia Group B study

Cancer
J J KirshnerA J Gottlieb

Abstract

In a pilot study, Cancer and Leukemia Group B (CALGB) incorporated etoposide into primary combination therapy for advanced Hodgkin disease. Thirty-six evaluable patients were treated with two or three courses of methotrexate, vincristine, prednisone, leucovorin, etoposide, and cyclophosphamide (MOPLEC), and then treated with five to seven additional courses of a known "curative" regimen: nitrogen mustard, vinblastine, prednisone, and procarbazine (MVPP). After treatment with MOPLEC, there were 16 complete responders (44%) and 18 partial responders (50%). One patient had progressive disease and one patient was taken off study after an anaphylactic reaction to etoposide. After completing the entire protocol, 32 patients achieved complete remission (CR) (89%) and 3 achieved partial remission (PR) (8%). Five CR patients have relapsed and three additional patients have died in CR without recurrence. At 36 months, the estimated failure-free survival is 61% and overall survival is 72%. This combination, which includes etoposide, is active for the primary treatment of advanced Hodgkin disease.

References

Dec 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R E van RijswijkJ Verbeek
Apr 1, 1982·The New England Journal of Medicine·A SantoroP Valagussa

❮ Previous
Next ❯

Citations

Jun 3, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carolyn Compton

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.